Skip to content
Search

Latest Stories

Kangana Ranaut nails it as a fighter pilot in the first look of Tejas

We all know that Kangana Ranaut will be seen playing the role of IAF pilot in RSVP’s next production venture titled Tejas. Today, the makers have unveiled the first look of the actress as a fighter pilot and she has nailed it.

The actress’ team took to Instagram to share her look from the film. They posted, "For all the brave hearted and strong headed women in Uniform who make sacrifices for our nation day in and day out .... Kangana to  play an airforce pilot in her next , titled - #TEJAS #KanganaRanaut @team_kangana_ranaut #RonnieScrewvala @sarveshmewara @nonabains @rsvpmovies."


Talking about the film, producer Ronnie Screwvala stated, “We made an army-centric/army-based film with Uri: The Surgical Strike. Tejas is our dedication to the brave fighter pilots of the Indian Air Force, who always put the country first. We are excited and honoured to share this brave story with viewers and hope it inspires many more women to join the Air Force.”

Kangana further added, “Very often the sacrifices made by our brave women in uniform go unnoticed by the nation. Tejas is a film where I have the honour of playing the role of one such Air Force pilot that puts country before self. I hope we instill a sense of patriotism and pride in the youth of today with this film. I am looking forward to the journey with Sarvesh and Ronnie on this one.”

Directed by Sarvesh Mewara, Tejas will start rolling in summer this year and it is slated to release in April 2021.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less